Abstract
Physiological rapid eye movement (REM) sleep termination is vital for initiating non-REM (NREM) sleep or arousal, whereas the suppression of excessive REM sleep is promising in treating narcolepsy. However, the neuronal mechanisms controlling REM sleep termination and keeping sleep continuation remain largely unknown. Here, we reveal a key brainstem region of GABAergic neurons in the control of both physiological REM sleep and cataplexy. Using fiber photometry and optic tetrode recording, we characterized the dorsal part of the deep mesencephalic nucleus (dDpMe) GABAergic neurons as REM relatively inactive and two different firing patterns under spontaneous sleep–wake cycles. Next, we investigated the roles of dDpMe GABAergic neuronal circuits in brain state regulation using optogenetics, RNA interference technology, and celltype-specific lesion. Physiologically, dDpMe GABAergic neurons causally suppressed REM sleep and promoted NREM sleep through the sublaterodorsal nucleus and lateral hypothalamus. In-depth studies of neural circuits revealed that sublaterodorsal nucleus glutamatergic neurons were essential for REM sleep termination by dDpMe GABAergic neurons. In addition, dDpMe GABAergic neurons efficiently suppressed cataplexy in a rodent model. Our results demonstrated that dDpMe GABAergic neurons controlled REM sleep termination along with REM/NREM transitions and represented a novel potential target to treat narcolepsy.
Similar content being viewed by others
Introduction
The periodic rhythm and continuity are essential for sleep physiology1,2. For continuous sleep in healthy human, rapid eye movement (REM) sleep follows non-REM (NREM) sleep several times during a typical night of sleep, while reductions in NREM sleep, disinhibition of REM sleep, and insomnia usually accompanied by non-consolidated sleep3. REM sleep was first described in 1953 by Kleitman and Aserinsky as regularly occurring “active sleep” in human infants, which is distinct from the quiescent sleep periods known as NREM sleep4. Of the rapid-eye-movements produced by bursting of oculomotor muscles, REM sleep is also characterized by desynchronized cortical electroencephalogram (EEG), high-amplitude theta waves, and muscle atonia5. REM sleep is associated with brain development6,7 and memory8,9. Dysregulation of REM sleep leads to numerous sleep disorders, including narcolepsy10,11. Although previous studies have described several brain regions that contribute to the promotion of REM sleep, such as the sublaterodorsal nucleus (SLD), ventral medulla, lateral hypothalamus (LH), etc12,13,14,15, the core mechanisms controlling the termination of REM sleep and REM/NREM alternations have been paid less attention to. Previous studies reveal that the monoaminergic neurons in the brainstem cease firing specifically during REM sleep, including serotonergic neurons from the raphe nuclei and noradrenergic neurons from the locus coeruleus (LC)16,17. Since the 1970s, non-monoamine-based inhibitory neurons in the ventrolateral periaqueductal gray matter/the deep mesencephalic nucleus (vlPAG/DpMe) have been reported as key parts of REM sleep inhibition18,19,20. However, the vital mechanisms of REM-sleep cessation are still controversial, and the neural mechanism underlying the maintenance of the REM sleep necessary for living and termination of endless REM sleep or REM-like pathological sleep remains largely uncertain.
In 1975, Petitjean et al. reported that electrical destruction of the dorsal norepinephrine bundle (including vlPAG/DpMe) in the mesencephalon induced an increase in REM sleep21. Consistently, chemical lesion of the area ventrolateral part to the vlPAG, the dorsal part of the deep mesencephalic nucleus (dDpMe, also called lateral pontine tegmentum) increased excessive REM sleep in mice20. Boissard et al. found the vlPAG/DpMe GABAergic neurons projecting to the SLD, the key REM sleep center22. Furthermore, dDpMe GABAergic (dDpMeGABA) neurons were found to be activated by REM-sleep deprivation23. Recent research reported a cluster of neurons expressing Atoh1 derived from the hindbrain that inhibited REM sleep by the dDpMe18. In humans, lesions of pons containing the dDpMe caused cataplexy and visual hallucinations due to excessive REM sleep24,25. However, direct evidence proving dDpMeGABA neurons as the essential elements in REM sleep regulation and REM-related disorders was still not sufficient. It was yet to be reported that how the real-time manipulation of dDpMeGABA neurons would affect REM, NREM, and wake state transitions.
In the current study, we applied fiber photometry and multichannel recording in vivo to investigate the spontaneous activity of dDpMeGABA neurons corresponding to REM sleep. In addition, we used optogenetics26, and RNA interference to reveal the crucial role of dDpMeGABA neurons in REM-sleep termination and sleep continuity. Finally, we applied the optogenetic manipulation in a virus-based orexin neuron-lesioned rodent model to investigate the cure effect of dDpMeGABA neurons on cataplexy. These findings may provide further insights into the pathophysiology of narcolepsy and reveal potential therapeutic avenues for sleep disorders.
Results
Spontaneous activity of dDpMeGABA neurons across different brain state transitions
First, we assessed the population activity of dDpMeGABA neurons across spontaneous sleep–wake states using fiber photometry technology27,28. To this end, we injected a Cre-dependent adeno-associated virus (AAV) encoding the fluorescent calcium indicator GCaMP6f into the dDpMe of GAD2-IRES-Cre knock-in mice (n = 5) (Fig. 1a and Supplementary Fig. S1a). The dDpMe is located in the mesopontine region of the brainstem as previous studies claimed, which is also called lateral pontine tegmentum20,23,29. Our results showed that GCaMP6f fluorescence signals were the lowest during REM sleep and higher during wakefulness or NREM sleep (Fig. 1b). The mean normalized fluorescence signals indicated that the activity of dDpMeGABA neurons in REM sleep was lower than that in NREM sleep or wakefulness (Fig. 1c). When comparing the mean normalized fluorescence signal transitions across brain states, we found obvious alterations in the population activity of dDpMe GABAergic neurons (Fig. 1d and Supplementary Fig. S1b). Notably, the activity of these neurons increased swiftly across REM-to-wake and NREM-to-wake transitions, and decreased slightly across NREM-to-REM sleep transitions.
We next applied in vivo multichannel recording to identify whether dDpMeGABA neurons have heterogeneity of neural activity. We recorded ChR2-tagged single-cell activity in GAD2-Cre mice during the sleep–wake cycle using optic tetrodes and electroencephalogram(EEG)/electromyography (EMG) signals synchronously (Fig. 1e and Supplementary Fig. S1c). Single units exhibiting reliable laser-evoked spiking at short latencies (<8 ms) were identified as GABAergic neurons. Typical traces of EEG/EMG and the firing rate showed that there were two types of ChR2-tagged neurons in the dDpMe (Fig. 1g) as Type 1 with short half-wavelength, low amplitude, and REM relatively inactive and Type 2 with long half-wavelength and high amplitude (Fig. 1f). Mean firing rate of Type 1 neurons showed a marked increase from REM→Wake, REM→NREM, NREM→Wake and a decrease from NREM→REM, Wake→NREM, whereas the activity of Type 2 neurons has the opposite change (Fig. 1h; Supplementary Fig. S1d). To quantify the relative firing rates of each neuron in different brain states, we calculated REM–Wake vs REM–NREM activity difference. Of the 35 identified GABAergic neurons, 22 neurons almost fell in the bottom left quadrant (Fig. 1i), indicating that these Type 1 neurons were mostly REM sleep relatively inactive. The other neurons were Type 2 neurons, which almost fell in the right quadrant. The mean firing rates of these neurons were more active during REM and NREM sleep than wakefulness (Fig. 1i). In addition, we stated that the firing patterns of Type 1 and Type 2 neurons were different as the firing rate of Type 1 neurons was the lowest in REM sleep whereas that of Type 2 neurons was the lowest in wakefulness versus NREM or REM sleep (Fig. 1j).
These findings reflect the physiological activity of GABAergic neurons in the dDpMe (including Type 1 and 2 neurons) changes upon transitions from REM sleep to NREM sleep or wakefulness. It suggests their participation in the regulation of REM sleep and state transitions.
Activation of dDpMeGABA neurons suppressed REM sleep and transferred REM sleep to NREM sleep
To investigate the roles of the dDpMeGABA neurons in REM sleep, we applied targeted optogenetic stimulation via bilateral stereotaxic microinjections of AAV vectors carrying Cre-dependent ChR2-mCherry or mCherry26,30 into the dDpMe of GAD2-IRES-Cre mice (Fig. 2a and Supplementary Fig. S2a). Whole-cell recordings in brain slices revealed that ChR2-positive dDpMeGABA neurons were depolarized with high temporal precision after 470-nm light stimulation (Supplementary Fig. S2b). Based on in vitro fidelity tests and in vivo latency comparisons, we selected 30 Hz as the light-stimulation frequency for subsequent experiments (Supplementary Fig. S2b). To quantify the effect, we aligned all trials from five mice by the time of laser stimulation. We found a sharp decrease in REM sleep, a rapid decrease within 10 s after laser onset, and a complementary increase in NREM sleep. In addition, REM sleep was found to rebound obviously after laser delivery (Fig. 2b). In detail, blue-light delivery in mice during REM sleep immediately terminated theta-dominated REM sleep, with a latency of 1.40 ± 0.20 s, and induced a rapid entry into the delta-dominated NREM sleep (Fig. 2c and Supplementary Fig. S2c). When REM and NREM bouts were quantified in 4 s epochs during light stimulation, REM sleep was dramatically decreased, and NREM sleep was significantly increased compared to that of the control group (93.5 ± 4.2%; Fig. 2d, e). Furthermore, light stimulation during wakefulness or NREM sleep was found to prolong NREM sleep and enhance wake-to-NREM transitions (Supplementary Fig. S2d–g). These findings demonstrated that dDpMeGABA neuronal activation effectively promoted transitions from REM sleep or wakefulness to NREM sleep. Additionally, we found that the duration of the wake episodes appearing after light-induced REM sleep suppression was significantly decreased by 60.5% (P = 4.41 × 10−3), whereas the duration of NREM-sleep episodes after the suppression of REM sleep was increased by 82.43% (P = 0.032) (Supplementary Fig. S2h). Furthermore, we found that after dDpMeGABA neuronal activation, the light-suppressed REM-sleep duration negatively correlated with re-occurrent REM-sleep duration, whereas the light-suppressed REM-sleep duration positively correlated with time intervals between REM cessation and re-occurrence (Supplementary Fig. S2i). Taken together, these findings demonstrated that the optogenetic activation of dDpMeGABA neurons immediately terminated REM sleep and initiated NREM sleep as well as increasing wake-to-NREM transitions. Moreover, a prolonged re-occurrent REM-sleep duration was observed when the light stimulation was terminated.
Inactivation of dDpMeGABA neurons induced excessive REM sleep and promoted NREM-to-REM transitions
Next, we stereotaxically injected AAV constructs carrying Cre-dependent eNpHR (an inhibitory optogenetic protein) or eYFP (control) into the dDpMe of GAD2-IRES-Cre mice. We successfully labeled dDpMeGABA neurons by immunohistochemistry and assessed their activity via patch-clamp recordings (Fig. 2f and Supplementary Fig. S3a, b). We aligned all trials from six mice with the timeline of laser stimulation and found fast induction of REM sleep within 20 s after laser onset and a complementary decrease in NREM sleep (Fig. 2g). In comparison with that in dDpMeGABA-eYFP mice, continuous yellow-light delivery for 60 s during NREM sleep effectively initiated REM sleep in dDpMeGABA-eNpHR mice with a significant increase in theta ratio (Fig. 2i, h, and Supplementary Fig. S3c). The latency to REM sleep induced by yellow-light delivery to dDpMe GABA-eNpHR neurons was 18.49 ± 1.98 s (Supplementary Fig. S3c). The major-stage probability of REM sleep during yellow-light delivery was drastically increased from 6.4% in the control group to 61.1% in dDpMeGABA-eNpHR mice (Fig. 2j). In contrast, optogenetic inhibition of dDpMeGABA neurons during REM sleep or wakefulness did not alter these behavioral stages (Supplementary Fig. S3d–g). Furthermore, we identified subsequent changes in the REM/NREM sleep cycle after yellow-light delivery. The durations of both REM sleep and wakefulness following optogenetic inhibition of dDpMeGABA neurons were significantly increased (65.12% and 79.66%, respectively, P < 0.05; Supplementary Fig. S3h). Similar to dDpMeGABA neuronal activation, we found that the duration of REM sleep induced by optogenetic inhibition of dDpMeGABA neurons positively correlated with both re-occurrent REM sleep duration and REM-REM intervals (Supplementary Fig. S3i). These findings demonstrated that optogenetic inhibition of dDpMeGABA neurons induced excessive REM sleep, suppressed NREM sleep, and increased the probability of NREM-to-REM transitions.
Neural circuits of dDpMe GABAergic projections in regulating brain states
We next sought to clarify the neural pathway for the conversion of REM sleep to NREM sleep by GABAergic neurons in the dDpMe. To this end, AAV-DIO-ChR2-mCherry constructs were injected into the dDpMe and optical fibers were inserted into the SLD/medial parabrachial nucleus (MPB), LH, or paraventricular thalamus (PVT) to activate the axonal terminals of projecting dDpMeGABA neurons in GAD2-Cre mice (Fig. 3a–c, f–h and Supplementary Fig. S4a–d). The patch-clamp data showed that the light-evoked inhibitory postsynaptic potentials were completely blocked by SR95531, the GABAA receptor antagonist, but not the AMPA and NMDA receptor antagonists NBQX and D-APV, indicating that dDpMeGABA axonal activation mostly induced GABA release into SLD or LH neurons (Fig. 3e, j). Moreover, REM sleep was immediately blocked and NREM sleep was significantly increased in mice after optogenetic activation of the SLD/MPB or LH (Fig. 3c, h). In contrast, there was no effect in mice with activation of dDpMeGABA axonal terminals in the PVT (Supplementary Fig. S4a–c). Interestingly, the probability of brain states showed that photostimulation of terminals in the SLD/MPB or LH of dDpMeGABA-ChR2 mice significantly decreased REM sleep by inducing an immediate transition from REM to NREM sleep, which was in contrast to the findings observed in mCherry-expressing control mice. The pie charts and histograms show that REM-sleep probability decreased and NREM-sleep probability increased during light stimulation in the SLD/MPB or LH regions, but not in the PVT (Fig. 3d, i and Supplementary Fig. S4d–e). These results indicate that dDpMeGABA neurons suppressed REM sleep via the dDpMe-SLD/MPB and dDpMe-LH circuits.
GABAergic dDpMe-Glutamatergic SLD neural pathway is essential for controlling REM-sleep termination and REM-to-NREM transitions
The onset of REM sleep is controlled by the nuclei of REM sleep promotion, such as the glutamatergic neurons in the SLD and GABAergic neurons in the ventral medulla17, which are essential for REM initiation and maintenance12,13,14. The SLD plays a critical role in controlling REM sleep and muscle atonia, and 84% of the REM active neurons are glutamatergic13,31. It has been reported that SLD glutamatergic (SLDGlu) neurons play a key role in generating REM sleep20,32. To test whether the SLDGlu neurons received dDpMe inputs, we mapped the whole-brain inputs to SLDGlu neurons via rabies viral (RV) retrograde tracing33,34 in the Vglut2-IRES-Cre mice (Supplementary Fig. S5a). The starter cells stained by yellow were co-infected with AAV helper viruses (GFP) and RV (DsRed), and the violet neurons presented ChAT immunoreactive signals for the laterodorsal tegmental nucleus and motor trigeminal nucleus, which were the border of the SLD (Supplementary Fig. S5b, c). To our surprise, we found that the dDpMe contributed the highest percentage of inputs to SLD glutamatergic neurons (9.11 ± 0.85%), whereas the vlPAG, LH, and lateral paragigantocellular nucleus contributed 3.08% ± 0.41%, 2.40% ± 0.21%, and 1.25% ± 0.34%, respectively (Supplementary Fig. S5d). A representative section revealed RV-DsRed-labeled presynaptic input neurons projecting to the SLDGlu neurons intensively distributed in the dDpMe, and dDpMe neurons double-stained with GAD1 mRNA and DsRed comprised 68.36% ± 3.95% of all dDpMe DsRed neurons (Supplementary Fig. S5e–g). These results indicate that dDpMe GABAergic (dDpMeGABA) neurons are one of the major sources of neural inputs to SLDGlu neurons.
To determine whether SLDGlu neurons are necessary for dDpMeGABA neurons to control REM-to-NREM transitions, we used short-hairpin RNAs (shRNAs) targeting Slc17a6 mRNA that encodes vesicular glutamate transporter 2 (Vglut2)12,33, to block synaptic glutamate release from SLD neurons. We verified the absence of Vglut2 mRNA by in situ hybridization of brain sections from shVglut2-mice compared to Vglut2 mRNA expression in shCtrl-injected mice (Fig. 4a, b, and Supplementary Fig. S6a). REM sleep was not induced by inhibition of dDpMeGABA neurons after blocking glutamatergic neurotransmission in the SLD, while REM sleep was enhanced in dDpMeGABA-eNpHR/SLD shCtrl mice. Compared to blue-light stimulation (control), a shortened mean latency from 112.80 ± 3.27 s to 44.19 ± 8.24 s (Supplementary Fig. S6b) and increased probability of NREM-to-REM transitions from 4.2% to 56.1% were revealed in dDpMeGABA-eNpHR/SLD shCtrl mice after stimulation with yellow light (Fig. 4c, e). In contrast, yellow-light inhibition failed to enhance REM sleep in dDpMeGABA-eNpHR mice injected with shVglut2 into the SLD (Fig. 4d, f). In addition, we found that the mice with SLD glutamate release deficiency without manipulation of GABAergic neurons in the dDpMe showed a slight decrease in REM-sleep amounts over 24 h from 111.50 ± 9.68 s to 83.38 ± 5.27 s compared to control mice (t = 2.55, P = 0.03; Supplementary Fig. S6c), and atonia increased after shRNA inhibition of the SLD in mice (Supplementary Fig. S6d, e), which is consistent with Sara Valencia Garcia et al. reported in 201712. These data demonstrated that the suppression of the dDpMeGABA–SLDGlu pathway is responsible for initiating REM sleep.
Because AAV injections into the SLD inadvertently included a small portion of glutamatergic PB neurons, we specifically injected shVglut2 into the PB of dDpMeGABA-eNpHR mice (Supplementary Fig. S7a). However, we found that the inactivation of glutamatergic neurotransmission in the PBGlu did not suppress REM-sleep induction by optogenetic inhibition of dDpMeGABA neurons (Supplementary Fig. S7b, c), suggesting that the dDpMeGABA–PBGlu pathway was not required for REM-sleep suppression.
Collectively, the data demonstrated that SLDGlu neurons are essential for REM-sleep suppression of dDpMeGABA neurons.
dDpMe GABAergic neurons relieved cataplexy in orexin-neural-lesion mice
To determine the roles of dDpMe GABAergic neurons in cataplexy, we applied optogenetic activation of dDpMe GABAergic neurons in conditional orexin-neural-lesion mice. We injected Vgat-ChR2-mCherry AAV viruses into the dDpMe to target GABAergic neurons, and injected orexin-Cre/dio-caspase-3 mixed AAV viruses into the LH area. Typical images showed orexin-immunoreactive LH area had no orexin expression after 2 weeks (Fig. 5a) and that AAV-GFP virus-infected neurons appeared like orexin-immunoreactive neurons (Supplementary Fig. S8a). Moreover, most of mCherry-labeled Vgat neurons were GAD2 mRNA-positive and largely co-localized with GABA (Fig. 5a and Supplementary Fig. S8b). According to the previous studies, we defined the criteria for cataplexy as described in detail in Materials and Methods35. As the chocolate was commonly used as emotionally rewarding stimuli to trigger cataplexy in mice36,37,38, we fed the mice chocolate during the active period. We found that orexin-caspase-3 mice occurred cataplexy with sudden muscle weakness and REM-like sleep during wakefulness (Fig. 5b and Supplementary Video S1) and exhibited a high amount of cataplexy (F(1,72) = 104.7, P < 0.001, ANOVA; Fig. 5c, left). The average amount of cataplexy during the dark period was 45.06 ± 4.30 min in orexin-neural-lesion mice, while the episode number and mean duration of cataplexies were 47.17 ± 3.01/12 h and 56.70 ± 3.37 s, respectively (Fig. 5c, right). Besides, wakefulness decreased accompanied by REM sleep increasing in the dark phase after lesion of orexin neurons (Supplementary Fig. S8c).
We next investigated whether cataplexy was regulated by dDpMe GABAergic neurons. We found that the cataplexy attacks were shut down after applying 470 nm-light stimulation in dDpMe GABAergic neurons for 120 s. In comparison with that in yellow-light control delivery, 30 Hz 470 nm-light delivery to Vgat-ChR2 neurons effectively and sharply curbed cataplexy attacks in orexin-caspase-3 mice (Fig. 5d and Supplementary Video S2). The probability of cataplexy during 470 nm delivery was drastically decreased and the theta ratio, the ratio of the power within the theta band (6–10 Hz) to the power within whole band, which is dominant in REM sleep and cataplexy (Fcataplexy(1,1548) = 115.50, P < 0.001; Ftheta(1,1638) = 26.22, P < 0.001, two-way ANOVA; Fig. 5e, left), and the probability of NREM sleep and wakefulness increased correspondingly (Supplementary Fig. S9a). The pie chart clearly showed that after 470 nm light delivery, cataplexy was abolished and NREM sleep almost tripled compared to control light stimulation. Moreover, the EMG integral during 470 nm light delivery in cataplexy divided by the baseline during NREM sleep was increased significantly compared to that during 593 nm light delivery or baseline in cataplexy (FEMG(3.18) = 14.17, P < 0.001; Fig. 5e, right). To investigate the long-lasting effect of dDpMe GABAergic neurons on cataplexy, we applied 30 Hz 470 nm, 5 ms, 5 s per 30 s light delivery in dDpMe GABAergic neurons for 3 h after feeding the mice with chocolate. The amount of cataplexy per hour was decreased significantly (F(1,72) = 7.12, P = 0.0094; Fig. 5f, g), and the total amount of cataplexy for 3 h at 470 nm delivery was decreased significantly from 13.85 ± 2.58 min to 1.88 ± 0.24 min (t = 4.61, P = 0.0036, unpaired t-test; Fig. 5g). At the same time, the time course or total amount of NREM, REM, and wakefulness did not change significantly during or after light stimulation (Supplementary Fig. S9b). Therefore, we reveal that dDpMe GABAergic neurons play an important role in inhibiting cataplexy attacks.
Furthermore, to investigate whether the suppression of the cataplexy is directly from the projection to the LH or other brain regions, we applied optogenetics to stimulate the downstream of dDpMeGABA neurons in the cataplexy model (Supplementary Fig. S10). As a result, we found that not only dDpMeGABA-LH pathway but also the dDpMeGABA-SLD pathway inhibited cataplexy.
Taken together, these findings show that the dDpMeGABA-SLDGlu neural circuit is essential for REM sleep termination and REM-to-NREM sleep transition, and that dDpMeGABA neurons are vital to relieve cataplexy attacks (Supplementary Fig. S11).
Discussion
The present findings revealed that substantial dDpMeGABA neurons are REM relatively inactive and the activity changed across state transitions, providing strong evidence that dDpMeGABA neurons control REM-sleep termination and promote REM-to-NREM transitions as well as increasing wake-to-NREM transitions via SLD glutamatergic and LH neurons. We built a rodent cataplexy model, which mimicked the cataplexy attacks observed in the transgenetic orexin-KO mouse model established by Chemelli et al. in 199939. We demonstrated that celltype-specific manipulation of dDpMe inhibitory neurons abolished cataplexy attacks in orexin neural lesion mice. Furthermore, we also revealed that REM-sleep induction can occur within seconds via dDpMeGABA neuronal inhibition.
As previous data have shown, there are REM relatively active neurons and REM relatively inactive neurons in the laterodorsal tegmental nucleus40, pedunculopontine tegmental nucleus41,42 or vlPAG19. Comparing the neurons in these brainstem nuclei, the population activity of dDpMeGABA neurons was found to be REM relatively inactive by fiber photometry recording of calcium signals. By spike sorting, we identified that dDpMeGABA neurons comprise Type1 and Type2 subpopulations. The in vivo optical tetrode recording in combination with the Cre-loxp system was effective for identifying the cell-type-specific neurons. The method to acquire the activity of specific neurons was faster and more precise than that involve analyzing discharge characteristics of neurons used in previous studies43. Based on in vivo optical tetrode recording, we found Type 2 neurons are more active during REM sleep, and the activity of Type1 neurons is lowest in REM sleep and highest in wakefulness. Combining with population activity of dDpMe neurons by fiber photometry, Type 1 neurons possibly occupy dominantly the population in dDpMe. We suppose the Type 2 neurons are more likely to inhibit REM-promoting neurons (such as the SLD neurons) constantly during REM sleep whereas Type 1 neurons are supposed to inhibit REM-promoting neurons just before REM to other states.
By applying virus-based tracing and optogenetics, we identified the neural circuits of the dDpMe, which may be useful to establish their physiological and pathological function in the future. Genetically engineered RV is widely used in neuroscience for its cell-type-specific infection of neurons, the fact that it does not affect passing neuronal tracts, and its effective passage across the known synaptic connections44. Accordingly, using RV-mediated retrograde tracing in Vglut2-IRES-Cre mice, we demonstrated that the dDpMe is the most dominate inputs to SLD glutamatergic neurons. This result was consistent with previous non-neuronal selective findings using cholera toxin subunit B retrograde tracing22. These studies may indicate that the dDpMe GABAergic neurons play a key role in SLD neuronal-related functions, such as the switch of REM sleep and REM sleep behavior disorders. Besides the dDpMeGABA–SLDGlu circuit, we showed that the dDpMeGABA-LH circuit is crucial to REM-sleep control. It has been proposed that the LH modulates REM sleep by REM-sleep-promoting melanin-concentrating hormone (MCH) neurons and wake-promoting orexin/hypocretin neurons15,45. Indeed, Kroeger et al. demonstrated the importance of MCH neurons to dDpMe/vlPAG pathways for regulating REM sleep46. In this study, we identified dDpMe–LH pathways that participated in REM-sleep control, suggesting that dDpMeGABA neurons send neuronal inputs to LH REM-promoting neurons, such as MCH neurons, to suppress REM sleep and cause alternative behavioral states. As the LH is the key node of substantial physiological and emotional activity, the bidirectional pathways of dDpMe–LH may be involved in regulating anxiety, stress, and insomnia.
Our work demonstrates a novel neuronal mechanism overlapping REM sleep and cataplexy inhibition, which was crucial for understanding the dysfunctional cycling of sleep stages and narcolepsy. In narcolepsy, owing to the lack of excitatory orexin inputs to the REM-inhibitory system of the brainstem (dDpMe, LC, vlPAG, etc.), positive emotions activate the limbic system, which inhibits the REM-inhibitory system and disinhibits the descending inhibitory systems during cataplexy. Systemic pharmacological medicines exist for treating cataplexy, such as tricyclic antidepressants, including protriptyline and clomipramine, but their anticholinergic side effects have limited their application47. Nowadays, sodium oxybate is considered as one of the most effective drugs for severe cataplexy, whereas its precise mechanism of action remains obscure48. Our work showed that when orexin neurons were damaged (orexin-caspase-3 lesion) and positive emotions were introduced (chocolate), activation of dDpMe GABAergic neurons still strongly inhibited cataplexy. The results revealed that dDpMe GABAergic neurons play vital roles in cataplexy. The ability of GABAergic neurons in the dDpMe to control REM-to-NREM transitions and relieve cataplexy might facilitate future research on the treatment of narcolepsy. Based on the evidence of Anaclet et al. 201149 and Zoltan et al. 201931, the SLD probably is the downstream of dDpMe GABAergic neurons for relieving cataplexy. When orexinergic excitatory inputs to the dDpMe was interrupted by orexin lesion in the cataplexy model, the GABAergic projects to SLD will be inactive, which lead the SLD to be disinhibited and induce cataplexy. When dDpMe GABAergic neurons were activated, the hyper-excited SLD will be inhibited and cataplexy attacks were curbed immediately. On the other hand, Naganuma et al. in 2018 found that MCH neurons contribute to dysregulation of REM sleep in narcolepsy50, suggesting that the LH might also be the downstream of dDpMe GABAergic neurons for relieving cataplexy. In our study, we proved that both of dDpMeGABA–LH and dDpMeGABA–SLD pathways inhibited cataplexy in orexin lesion mice.
In conclusion, we revealed that the neural activity of dDpMeGABA neurons was firmly fixed with brain states. We also identified an essential role of dDpMeGABA neurons in REM sleep termination and REM-to-NREM sleep transitions, primarily through dDpMeGABA–SLD/LH neural circuits. Moreover, we uncovered that dDpMeGABA neurons represent a vital switch in cataplexy, which would provide a novel target for the treatment of narcolepsy in the future.
Materials and methods
Mice
Optogenetic manipulations, fiber photometry, in vivo multichannel recording, and RNA-inference experiments were performed in male GAD2-IRES-Cre mice (Jackson Laboratory stock 010802) or male Vglut2-IRES-Cre mice (Jackson Laboratory stock 016963). Descriptions in detail are in Supplementary methods.
Viral vectors
Viral vectors used for retrograde tracing and behavioral experiments were packaged by BrainVTA Co., Ltd. (Wuhan, China) or Tailtool Bioscience Co., Ltd. (Shanghai, China). The titer of the EnvA-pseudotyped, glycoprotein (RG)-deleted, and DsRed-expressing rabies virus (RV-EnvA-ΔRG-DsRed, Brain VTA, # R01002) was ~2 × 108 infecting units/mL. The two adeno-associated virus (AAV) vectors, namely, AAV-EF1α-DIO-TVA-GFP (Brain VTA, # PT-0165) and AAV-EF1α-DIO-RV-G (Brain VTA, # PT-0023), were packaged into the 2/9 AAV serotype and titrated at ~3 × 1012 genome copies/mL51,52,53. The titer of the AAV-EF1α-DIO-ChR2-mCherry (Taitool Bioscience, # S0170-9), AAV-EF1α-DIO-mCherry (Taitool Bioscience, # S0312-9), AAV-EF1α-DIO-eNpHR-eYFP (Taitool Bioscience, # S0178-9), AAV-EF1α-DIO-eYFP (Taitool Bioscience, # S0320-9), AAV-Vgat-ChR2-mCherry (Brain VTA, # PT-0643), AAV-Orexin-Cre (promoter sequence designed from Mus musculus hypocretin (Hcrt), NM_010410, 1513 bp, Brain VTA, # PT-1573), AAV-EF1α-DIO-taCap3-TEVp (Taitool Bioscience, # S0236-9), and AAV-EF1α-DIO-eGFP (Taitool Bioscience, # S0270-9) was ~3–5 × 1012 infecting units/mL. Yoan Cherasse kindly provided the AAV-shVglut2-mCherry (5.6 × 1012 particles/mL) and AAV-shCtrl-mCherry (4.5 × 1012 particles/mL) vectors12,54.
Surgeries and viral injections
Adult mice were anesthetized with isoflurane (5% induction, 1.5% maintenance) and placed in a stereotaxic apparatus (RWD Life Science, Shenzhen, China). Using a compressed air delivery system as previously described55, AAVs were slowly bilaterally microinjected (20 nL/min, the total volume of AAV the authors injected was 40–80 nL) into the dDpMe (AP: − 4.2 mm, ML: + 1.0 mm, DV: − 3.5 mm)51, SLD, AP: − 5.1 mm, ML: + 0.8 mm, DV: − 4.1 mm, or LH, AP: − 0.7 mm, ML: + 1.0 mm, DV: − 5.3 mm through a glass pipette. The glass pipette was left in place for an additional 20 min and was then slowly withdrawn. After three weeks, the mice used for in vivo studies were chronically implanted with EEG/EMG electrodes and fibers, the details are in Supplementary methods.
Vigilance state assessment
The vigilance states were automatically scored offline by SleepSign (Kissei Comtec, Nagano, Japan) into 4-s-epoch wake, NREM, REM sleep, or cataplexy according to standard criteria based on EEG and EMG waveforms. The states were examined visually and manually corrected if necessary. We defined wakefulness as desynchronized EEG and high levels of EMG activity, NREM sleep as synchronized, high-amplitude, low-frequency (0.5–4 Hz) EEG signals in the absence of motor activity, and REM sleep as having pronounced theta-like (6–10 Hz) EEG activity and muscle atonia56. Cataplexy was defined by muscle atonia lasting more than 10 s after more than 40 s of wakefulness, and REM-like theta activity in the EEG35.
Optogenetic stimulation
We performed optogenetic experiments during 12:00 p.m.-00:00 a.m. 3–4 weeks after injection of AAV-expressing eNpHR or ChR2. The optical fiber cannulas were attached to a rotating joint (FRJ_FC-FC, Doric Lenses, Canada) to relieve torque. The joint was connected via a fiber to a 473-nm blue laser or a 590-nm yellow laser, and the light pulses were generated through a stimulator (Master-8, A.M.P.I., Israel). For optogenetic activation of GABAergic dDpMe neurons or their axonal terminals in normal mice, each trial consisted of a 1-30-Hz pulse train lasting for 120 s using a 473-nm blue laser during inactive period (6–8 mW at the fiber tip, Shanghai Optogenetic stimulation in vivo Laser, China). For optogenetic inhibition of dDpMeGABA neurons in normal mice, each trial consisted of continuous light lasting for 60 s using a 590-nm yellow laser during inactive period (6–8 mW at the fiber tip, Shanghai Optogenetic stimulation in vivo Laser, China). The inter-trial interval of optogenetic stimulation was more than 10 min. For optogenetic activation of GABAergic dDpMe neurons or their axonal terminals in orexin neuronal lesion mice, each trial of acute stimulation experiments consisted of a 30-Hz pulse train lasting for 120 s using a 473-nm blue laser during active period, whereas chronic stimulation experiments were performed by 30-Hz pulse train (5 s per 30 s) lasting for 3 h (6–8 mW at the fiber tip, Shanghai Optogenetic stimulation in vivo Laser, China).
Fiber photometry
Following AAV-EF1α-DIO-GCaMP6f virus injection, an optical fiber (125 μm O.D., 0.37 numerical aperture (NA); Newdoon, Shanghai) was placed in a ceramic ferrule and inserted toward the dDpMe. Following the 2-week recovery period from the virus injection and implantation surgery, fiber-photometry experiments were performed as previously described27,57,58,59. The photometry analog voltage signals were digitized at 512 Hz and recorded by a Power 1401 digitizer and Spike2 software (CED, Cambridge, United Kingdom) simultaneously with polysomnographic recordings. The details of data analysis are in Supplementary methods.
Multichannel recording by optic tetrodes
To record the activity of dDpMe GABAergic neurons, we used a custom-built optode, consisting of an optical fiber (0.2-mm diameter) surrounded by 16 microwire electrodes (13 μm, Sandivik, Pt/Ir F562, USA) twisted into tetrodes. The optical fiber and electrodes were inserted into a screw-driven microdrive. The optode was slowly lowered in 25–50 μm steps to search for light-responsive neurons. The multichannel signals were digitized at 40 kHz and recorded by a 16-channel Plexon system and Omniplex software (Plexon, USA) simultaneously with polysomnographic recordings (digitized at 1 kHz). At the end of the experiment, electrolytic lesions were made by passing a current (100 mA, 10 s) through one or two electrodes to identify the end of the recording tract60. The details in sorting and analysis are in Supplementary methods.
Statistical analysis
Data were assessed using one-way or two-way repeated-measures ANOVAs followed by Sidak’s multiple-comparison tests. When appropriate, Student’s t-tests were used to determine statistical significance of pre-planned comparisons. Data are expressed as the means ± standard error of mean (SEM). The linear relationship of the sleep duration and interval was measured by the Pearson product-moment correlation coefficient. A P-value < 0.05 was considered statistically significant.
The details of retrograde tracing, electrophysiological experiments in vitro, immunohistochemistry, immunofluorescence, and in situ hybridization are in Supplementary methods.
Data availability
The data that support the findings of this study are available from the corresponding author upon reasonable request.
References
Kleitman, N. Basic rest-activity cycle–22 years later. Sleep 5, 311–317 (1982).
Le Bon, O. Relationships between REM and NREM in the NREM-REM sleep cycle: a review on competing concepts. Sleep Med. 70, 6–16 (2020).
Palagini, L., Baglioni, C., Ciapparelli, A., Gemignani, A. & Riemann, D. REM sleep dysregulation in depression: state of the art. Sleep Med. Rev. 17, 377–390 (2013).
Aserinsky, E. & Kleitman, N. Regularly occurring periods of eye motility, and concomitant phenomena, during sleep. Science 118, 273–274 (1953).
Siegel, J. M. In: Kryger, M. H., Roth, T., Dement W. C., (eds.). Principles and Practice of Sleep Medicine. Fourth Edition. W. B. Saunders, 120–135 (2005).
Mueller, A. D., Meerlo, P., McGinty, D. & Mistlberger, R. E. Sleep and adult neurogenesis: implications for cognition and mood. Curr. Top. Behav. Neurosci. 25, 151–181 (2015).
Wolfe, K. & Ralls, F. M. Rapid eye movement sleep and neuronal development. Curr. Opin. Pulm. Med. 25, 555–560 (2019).
Izawa, S. et al. REM sleep-active MCH neurons are involved in forgetting hippocampus-dependent memories. Science 365, 1308–1313 (2019).
Boyce, R., Glasgow, S. D., Williams, S. & Adamantidis, A. Causal evidence for the role of REM sleep theta rhythm in contextual memory consolidation. Science 352, 812–816 (2016).
Bixler, E. O. et al. Narcolepsy/cataplexy. III: Nocturnal sleep and wakefulness patterns. Int. J. Neurosci. 29, 305–316 (1986).
McCarley, R. W. Neurobiology of REM sleep. Handb. Clin. Neurol. 98, 151–171 (2011).
Valencia Garcia, S. et al. Genetic inactivation of glutamate neurons in the rat sublaterodorsal tegmental nucleus recapitulates REM sleep behaviour disorder. Brain 140, 414–428 (2017).
Clement, O., Sapin, E., Berod, A., Fort, P. & Luppi, P. H. Evidence that neurons of the sublaterodorsal tegmental nucleus triggering paradoxical (REM) sleep are glutamatergic. Sleep 34, 419–423 (2011).
Weber, F. et al. Control of REM sleep by ventral medulla GABAergic neurons. Nature 526, 435–438 (2015).
Jego, S. et al. Optogenetic identification of a rapid eye movement sleep modulatory circuit in the hypothalamus. Nat. Neurosci. 16, 1637–1643 (2013).
Scammell, T. E., Arrigoni, E. & Lipton, J. O. Neural circuitry of wakefulness and sleep. Neuron 93, 747–765 (2017).
Wang, Y. Q., Liu, W. Y., Li, L., Qu, W. M. & Huang, Z. L. Neural circuitry underlying REM sleep: A review of the literature and current concepts. Prog. Neurobiol. 204, 102106 (2021).
Hayashi, Y. et al. Cells of a common developmental origin regulate REM/non-REM sleep and wakefulness in mice. Science 350, 957–961 (2015).
Weber, F. et al. Regulation of REM and Non-REM sleep by periaqueductal GABAergic neurons. Nat. Commun. 9, 354 (2018).
Lu, J., Sherman, D., Devor, M. & Saper, C. B. A putative flip-flop switch for control of REM sleep. Nature 441, 589–594 (2006).
Petitjean, F., Sakai, K., Blondaux, C. & Jouvet, M. Hypersomnia by isthmic lesion in cat. II. Neurophysiological and pharmacological study. Brain Res. 88, 439–453 (1975).
Boissard, R., Fort, P., Gervasoni, D., Barbagli, B. & Luppi, P. H. Localization of the GABAergic and non-GABAergic neurons projecting to the sublaterodorsal nucleus and potentially gating paradoxical sleep onset. Eur. J. Neurosci. 18, 1627–1639 (2003).
Sapin, E. et al. Localization of the brainstem GABAergic neurons controlling paradoxical (REM) sleep. PLoS One 4, e4272 (2009).
Vita, M. G. et al. Visual hallucinations and pontine demyelination in a child: possible REM dissociation? J. Clin. Sleep. Med. 4, 588–590 (2008).
Joo, E. Y. et al. Cerebral perfusion abnormality in narcolepsy with cataplexy. Neuroimage 28, 410–416 (2005).
Yang, S. R. et al. The rostromedial tegmental nucleus is essential for non-rapid eye movement sleep. PLoS Biol. 16, e2002909 (2018).
Dong, H. et al. Dorsal striatum dopamine levels fluctuate across the sleep-wake cycle and respond to salient stimuli in mice. Front. Neurosci. 13, 242 (2019).
Li, Y. et al. Serotonin neurons in the dorsal raphe nucleus encode reward signals. Nat. Commun. 7, 10503 (2016).
Sherman, D. et al. Anatomical location of the mesencephalic locomotor region and its possible role in locomotion, posture, cataplexy, and Parkinsonism. Front. Neurol. 6, 140 (2015).
Yuan, X. S. et al. Striatal adenosine A2A receptor neurons control active-period sleep via parvalbumin neurons in external globus pallidus. Elife 6, e29055 (2017).
Torontali, Z. A., Fraigne, J. J., Sanghera, P., Horner, R. & Peever, J. The sublaterodorsal tegmental nucleus functions to couple brain state and motor activity during REM sleep and wakefulness. Curr. Biol. 29, 3803–3813 e3805 (2019).
Erickson, E. T. M., Ferrari, L. L., Gompf, H. S. & Anaclet, C. Differential role of pontomedullary glutamatergic neuronal populations in sleep-wake control. Front. Neurosci. 13, 755 (2019).
Guo, H. et al. Whole-brain monosynaptic inputs to hypoglossal motor neurons in mice. Neurosci. Bull. 36, 585–597 (2020).
Yuan, X. S. et al. Whole-brain monosynaptic afferent projections to the cholecystokinin neurons of the suprachiasmatic nucleus. Front. Neurosci. 12, 807 (2018).
Scammell, T. E., Willie, J. T., Guilleminault, C. & Siegel, J. M., International Working Group on Rodent Models of, N. A consensus definition of cataplexy in mouse models of narcolepsy. Sleep 32, 111–116 (2009).
Oishi, Y. et al. Role of the medial prefrontal cortex in cataplexy. J. Neurosci. 33, 9743–9751 (2013).
Hung, C. J., Ono, D., Kilduff, T. S. & Yamanaka, A. Dual orexin and MCH neuron-ablated mice display severe sleep attacks and cataplexy. Elife 9, e54275 (2020).
Mahoney, C. E., Agostinelli, L. J., Brooks, J. N., Lowell, B. B. & Scammell, T. E. GABAergic neurons of the central amygdala promote cataplexy. J. Neurosci. 37, 3995–4006 (2017).
Chemelli, R. M. et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 98, 437–451 (1999).
Boucetta, S., Cisse, Y., Mainville, L., Morales, M. & Jones, B. E. Discharge profiles across the sleep-waking cycle of identified cholinergic, GABAergic, and glutamatergic neurons in the pontomesencephalic tegmentum of the rat. J. Neurosci. 34, 4708–4727 (2014).
Kroeger, D. et al. Cholinergic, glutamatergic, and GABAergic neurons of the pedunculopontine tegmental nucleus have distinct effects on sleep/wake behavior in mice. J. Neurosci. 37, 1352–1366 (2017).
Van Dort, C. J. et al. Optogenetic activation of cholinergic neurons in the PPT or LDT induces REM sleep. Proc. Natl. Acad. Sci. USA 112, 584–589 (2015).
Sakai, K. Single unit activity of periaqueductal gray and deep mesencephalic nucleus neurons involved in sleep stage switching in the mouse. Eur. J. Neurosci. 47, 1110–1126 (2018).
Wickersham, I. R. et al. Monosynaptic restriction of transsynaptic tracing from single, genetically targeted neurons. Neuron 53, 639–647 (2007).
Eggermann, E. et al. The wake-promoting hypocretin-orexin neurons are in an intrinsic state of membrane depolarization. J. Neurosci. 23, 1557–1562 (2003).
Kroeger, D., Bandaru, S. S., Madara, J. C. & Vetrivelan, R. Ventrolateral periaqueductal gray mediates rapid eye movement sleep regulation by melanin-concentrating hormone neurons. Neuroscience 406, 314–324 (2019).
Nishino, S. & Mignot, E. Pharmacological aspects of human and canine narcolepsy. Prog. Neurobiol. 52, 27–78 (1997).
Reading, P. Cataplexy. Pract. Neurol. 19, 21–27 (2019).
Krenzer, M. et al. Brainstem and spinal cord circuitry regulating REM sleep and muscle atonia. PLoS One 6, e24998 (2011).
Naganuma, F. et al. Melanin-concentrating hormone neurons contribute to dysregulation of rapid eye movement sleep in narcolepsy. Neurobiol. Dis. 120, 12–20 (2018).
Chen, Z. K. et al. Whole-brain neural connectivity to lateral pontine tegmentum GABAergic neurons in mice. Front. Neurosci. 13, 375 (2019).
Wei, H. H. et al. Presynaptic inputs to vasopressin neurons in the hypothalamic supraoptic nucleus and paraventricular nucleus in mice. Exp. Neurol. 343, 113784 (2021).
Shi, X. et al. Whole-brain monosynaptic inputs and outputs of glutamatergic neurons of the vestibular nuclei complex in mice. Hear. Res. 401, 108159 (2021).
Li, Y. et al. Supramammillary nucleus synchronizes with dentate gyrus to regulate spatial memory retrieval through glutamate release. Elife 9, e53129 (2020).
Chen, L. et al. Basal forebrain cholinergic neurons primarily contribute to inhibition of electroencephalogram delta activity, rather than inducing behavioral wakefulness in mice. Neuropsychopharmacology 41, 2133–2146 (2016).
Fang, T. et al. Adenosine A2A receptor mediates hypnotic effects of ethanol in mice. Sci. Rep. 7, 12678 (2017).
Luo, Y. J. et al. Nucleus accumbens controls wakefulness by a subpopulation of neurons expressing dopamine D1 receptors. Nat. Commun. 9, 1576 (2018).
Yuan, M. Y. et al. Ablation of olfactory bulb glutamatergic neurons induces depressive-like behaviors and sleep disturbances in mice. Psychopharmacology 237, 2517–2530 (2020).
Dong, H. et al. Striatal neurons expressing dopamine D1 receptor promote wakefulness in mice. Curr. Biol. 32, 600–613 e604 (2022).
Li, Y. D. et al. Hypothalamic modulation of adult hippocampal neurogenesis in mice confers activity-dependent regulation of memory and anxiety-like behavior. Nat. Neurosci. 25, 630–645 (2022).
Acknowledgements
The authors thank Dr. Miao He (Fudan University) for kindly supplying us with GAD2-Cre mice and Dr. Zhen-Gang Yang (Fudan university) for kindly providing the probes to target mRNA molecules, Dr. Zhi-An Hu (Third Military Medical University, China) for helpful discussion. In addition, the authors thank Dr. Tian-Xiao Wang and Ms. Jing Ge for technical supports. This study was partly supported by the National Major Project of China Science and Technology Innovation 2030 for Brain Science and Brain-Inspired Technology (2021ZD0203400 to Z.-L.H.), the National Key Research and Development Program of China (2020YFC2005300, 2021YFC2501400 to W.-M.Q.), the National Natural Science Foundation of China (82020108014 and 32070984 to Z.-L.H.; 82071491 and 31871072 to W.-M.Q.; 81971238 to Y.-Y.L.), the Shanghai Science and Technology Innovation Action Plan Laboratory Animal Research Project (201409001800 to Z.-L.H.), Shanghai Municipal Science and Technology Major Project (2018SHZDZX01 to Z.-L.H), ZJLab, Program for Shanghai Outstanding Academic Leaders (to Z.-L.H), and Shanghai Center for Brain Science and Brain-Inspired Technology.
Author information
Authors and Affiliations
Contributions
Z.-K.C. and H.D designed and performed the behavior experiments, analyzed data, and wrote the paper. C.-W.L. and W.-Y.L. performed the electrophysiology experiments in vitro, behavior experiments, and analyzed data. Y.-N.Z. and W.X. performed the electrophysiology experiments in vivo and analyzed data. X.S. and Y.-Y.X. wrote code for electrophysiology experiments in vivo. F.-F.D., X.-S.Y., B.W. and Y.-Y.L. conceived the experiments and wrote the paper. Y.C. and Y.-D.L. provided viruses and data code. M.L. and F.H. provided helpful suggestions. Z.-L.H., F.-F.D. and W.-M.Q. conceived the experiments, analyzed data and wrote the paper.
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Chen, ZK., Dong, H., Liu, CW. et al. A cluster of mesopontine GABAergic neurons suppresses REM sleep and curbs cataplexy. Cell Discov 8, 115 (2022). https://doi.org/10.1038/s41421-022-00456-5
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41421-022-00456-5
- Springer Nature Singapore Pte Ltd.
This article is cited by
-
Insomnia-related rodent models in drug discovery
Acta Pharmacologica Sinica (2024)
-
Digital automation of transdermal drug delivery with high spatiotemporal resolution
Nature Communications (2024)
-
Neural Control of REM Sleep and Motor Atonia: Current Perspectives
Current Neurology and Neuroscience Reports (2023)